Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 2

2(28.6%)

Phase 3

1(14.3%)

7Total

Phase 1(4)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT02009449Phase 1Completed

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Role: collaborator

NCT03382899Phase 2Terminated

Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

Role: collaborator

NCT02923921Phase 3Completed

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

Role: collaborator

NCT03382912Phase 2Terminated

Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

Role: collaborator

NCT03554434Unknown

An Expanded Access Program for AM0010 (Pegilodecakin)

Role: collaborator

NCT04194892Phase 1Completed

A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants

Role: collaborator

NCT03267732Phase 1Completed

A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)

Role: collaborator

NCT03381547Phase 1Completed

A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)

Role: collaborator

All 8 trials loaded